僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Itolizumab （Anti-Human CD6 Recombinant Antibody） is a humanized recombinant anti-CD6 monoclonal antibody （MAb） targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis （RA）, COVID-19